Cloverleaf Bio, a spinout out of Yale, announced $33M in seed financing today that will help it advance its work on a tRNA platform in oncology

<p>Co-Founders Austin Draycott and Cole Lewis, describe the type of work they are doing (the lead program targets hepatocellular carcinoma) and the investors that participated in the financing, which include 4BIO Capital, AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund.</p>